This study aimed to assess the physical–chemical, and microbiological stability and investigate the color change of compounded minoxidil formulations in TrichoSolTM or TrichoFoamTM. HPLC analyses and antimicrobial effectiveness testing were conducted in concentrations from 1.0% to 7.0% of minoxidil. The color change was noticeable, but no other quality attribute was affected. No precipitation was observed, and the pH was relatively stable.

This study investigated whether Miodesin (10 µg/mL = IC80; 200 µg/mL = IC50) could exert anti-inflammatory and anti-proliferative effects against Lipopolysaccharides stimulation in endometrial and Candida albicans vaginal cell lines. The study concludes that Miodesin presents beneficial effects in the context of endometriosis, positively affecting the inflammatory and proliferative response.

The aim of this study was to validate the efficacy of a new ultraviolet C light disinfection system in different environmental conditions. The device was effective in the neutralization of airborne particles containing coronavirus genus samples, presenting >99.99% of inactivation rate in an aerosolization test.

The testing conducted for the DiluCap line of excipients showed that all products have suitable flow properties, hygroscopicity, biopharmaceutical performance, and stability; supporting the use of this line of excipients by the compounding pharmacies with proven functionality that saves time and guarantees efficacy and safety of hard-shell oral capsules formulations.

The purpose of this study was to investigate the homogeneity and resuspendability of SyrSpend SF suspensions. HPLC analysis was performed for 104 different formulations with 89 unique active pharmaceutical ingredients . All samples in SyrSpend SF were compliant with the specifications set by the British Pharmacopoeia.

In this bracketed study, benzoyl peroxide, cyproterone acetate, estriol, metronidazole, niacinamide, progesterone, retinoic acid, spironolactone, and tranexamic acid were evaluated for compatibility and stability in Cleoderm™. For most formulations, a beyond-use date (BUD) of 180 days was observed when stored at room temperature, except for retinoic acid (BUD 30 days).

A method to prepare 0.2% oral erlotinib cream, without resorting to a pure active pharmaceutical ingredient, was developed. The proposed formulation is stable for at least 42 days at room temperature in Nourivan cream with antioxidant properties.

This ex vivo study aimed to characterize the percutaneous absorption pharmacokinetics of tramadol 100mg/ml in Pentravan through feline inner pinna skin. The tramadol formulation was stable for three months at room temperature. Tramadol penetrated through the feline inner pinna skin, but considerable intra- and inter-individual variability in kinetics was observed.

This study assessed the beyond-use date (BUD) of seven APIs for topical use for alopecia in TrichoWash, TrichoCream, TrichoCond, and TrichoSol: All formulations presented a BUD of 6 months, except for latanoprost in TrichoCream and latanoprost in combination with minoxidil and finasteride in TrichoSol (BUD 3 months).

In this study, the beyond-use date of formulations containing estradiol, estriol, estrone, progesterone, and testosterone in combination, compounded with Fitalite, Versatile, and HRT Supreme Cream base was evaluated. A beyond-use date of 180 days was observed for all vehicles stored both at refrigerated and at room temperature.